Examining the Role of BTK Inhibitors in Mantle Cell Lymphoma
The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.
Source: onclive.com